Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of rheumatoid arthritis according to the revised 1987 criteria of the American College of Rheumatology
Female subjects who are not capable of becoming pregnant
Active disease defined as Disease Activity Score (DAS) 28 = 4.0 and at least one metacarpal-phalangeal finger (MCP) joint with either detectable vascularity or thickness
Stable doses of disease modifying anti-rheumatic drugs (DMARDs), (which can include but is not restricted to methotrexate, sulphasalazine and hydroxychloroquine in any combination) for 8 weeks prior to enrollment
Patients receiving methotrexate must be on stable folate supplements
Must have been on stable doses for 2 weeks prior to screening if using COX inhibitors
Signed consent form
The patient is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
You may not be if
The subject is using, or has used, oral glucocorticoids within 8 weeks of enrollment
The subject is currently receiving anti-rheumatic biological therapy (e.g. infliximab, adalimumab, etanercept or anakinra)
The subject received their final dose of infliximab or adalimumab within 3 months of enrollment
The subject received their final dose of etanercept or anakinra within 1 month of enrollment
The subject has received another investigational drug within 30 days
The subject drinks more than 28 units (male) or 21 units (female) of alcohol in a week
History of liver or renal disease in the 6 months prior to screening
The subject has a history of drug or other allergy
Subject is positive for Hepatitis B and C or HIV virus
The subject has positive pregnancy test
The subject has positive test for drugs of abuse
Clareo Health | A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.
